Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;18(6):645-658.
doi: 10.1002/pst.1954. Epub 2019 Jul 15.

Reference-based sensitivity analysis for time-to-event data

Affiliations

Reference-based sensitivity analysis for time-to-event data

Andrew Atkinson et al. Pharm Stat. 2019 Nov.

Abstract

The analysis of time-to-event data typically makes the censoring at random assumption, ie, that-conditional on covariates in the model-the distribution of event times is the same, whether they are observed or unobserved (ie, right censored). When patients who remain in follow-up stay on their assigned treatment, then analysis under this assumption broadly addresses the de jure, or "while on treatment strategy" estimand. In such cases, we may well wish to explore the robustness of our inference to more pragmatic, de facto or "treatment policy strategy," assumptions about the behaviour of patients post-censoring. This is particularly the case when censoring occurs because patients change, or revert, to the usual (ie, reference) standard of care. Recent work has shown how such questions can be addressed for trials with continuous outcome data and longitudinal follow-up, using reference-based multiple imputation. For example, patients in the active arm may have their missing data imputed assuming they reverted to the control (ie, reference) intervention on withdrawal. Reference-based imputation has two advantages: (a) it avoids the user specifying numerous parameters describing the distribution of patients' postwithdrawal data and (b) it is, to a good approximation, information anchored, so that the proportion of information lost due to missing data under the primary analysis is held constant across the sensitivity analyses. In this article, we build on recent work in the survival context, proposing a class of reference-based assumptions appropriate for time-to-event data. We report a simulation study exploring the extent to which the multiple imputation estimator (using Rubin's variance formula) is information anchored in this setting and then illustrate the approach by reanalysing data from a randomized trial, which compared medical therapy with angioplasty for patients presenting with angina.

Keywords: MNAR; missing data; multiple imputation; sensitivity analysis; time to event.

PubMed Disclaimer

Figures

Figure 1
Figure 1
RITA‐2 trial–Nelson‐Aalen cumulative hazard survival plots for all cause mortality (up to 8 y only 18 patients lost to follow‐up)
Figure 2
Figure 2
Time‐to‐event data–Jump to Reference
Figure 3
Figure 3
Proportionate increase in variance as censoring increases under (a) censoring at random and (b) Jump to Reference
Figure 4
Figure 4
Simulation results: exploration of information anchoring for two sample sizes and two hazard ratios. For each scenario, as the proportion of active arm censoring increases, each panel shows the evolution of the variance of the estimated hazard ratio calculated in four ways: (a) −+− information anchored variance; (b) −∘− Rubin's MI variance under Jump to Reference; (c) −×− E^[V^inf(β^)] when censored data recreated under Jump to Reference; and (d) −⋄− V^emp(β^MI) under Jump to Reference
Figure 5
Figure 5
Plot of the log cumulative hazard against time with Nelson‐Aalen estimates for the PTCA arm (upper dashed, red) and medical arm (lower dashed, black). The solid (red) line shows the estimated Weibull model log cumulative hazard for the medical arm when patients are censored at their first nonrandomized intervention and “Jump to PTCA arm”

References

    1. United States National Research Council . The Prevention and Treatment of Missing Data in Clinical Trials, Panel on Handling Missing Data in Clinical Trials, Committee on National Statistics, Division of Behavioral and Social Sciences and Education Washington DC: The National Academic Press; 2010.
    1. CHMP . Guidelines on missing data in confirmatory clinical trials. European Medicines Agency, download from http://www.ema.europa.eu, accessed 15 January 2014.
    1. CHMP . Ich e9 (r1) addendum on estimands and sensitvity analysis in clinical trials to the guidance on statistical principles for clinical trials. European Medicines Agency, download from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin...
    1. Scharfstein DO, Rotnitzky A, Robins JM. Adjusting for nonignorable drop‐out using semiparametric nonresponse models. J Am Stat Assoc. 1999;94(448):1096‐1120.
    1. Scharfstein DO, Robins JM, Eddings W, Rotnitzky A. Inference in randomized studies with informative censoring and discrete time‐to‐event endpoints. Biometrics. 2001;57:404‐413. - PubMed

Publication types